ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Civetta launches with $53 million to target propeller proteins

by Ryan Cross
December 12, 2019 | APPEARED IN VOLUME 97, ISSUE 48

The health-care investment firm Deerfield Management has launched a biotech start-up called Civetta Therapeutics with $53 million in series A financing. Civetta will develop small molecules that target β propeller proteins, which get their name from β-pleated amino acid sheets arranged in a circle like a propeller or pinwheel. The Cambridge, Massachusetts–based firm says β propeller proteins are important for protein-protein interactions and are implicated in cancer, metabolic diseases, and neurodegeneration.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment